A built-in 'hairpin' mechanism in CRISPR-Cas13 prevents rogue RNAs

The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
The Scientist

CRISPR Therapy: Progress and Prospects

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
Forbes

CRISPR: From Discovery To Clinic—And Charting A Path Forward

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Seeking Alpha

Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case

Intellia Therapeutics is pioneering in vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster ...
EurekAlert!

A built-in “hairpin” prevents rogue CRISPR RNAs

The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the emphasis has been on its underlying mechanisms and nucleases. In contrast, ...